Non Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2023’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)
- The report reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics and enlists all their major and minor projects
- The report assesses Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
89bio IncABIONYX Pharma SA
Acesis Holdings Corp
Afimmune Biopharma Ltd
Agentix Corp
Akero Therapeutics Inc
Albert Einstein College of Medicine
Alfasigma SpA
Algernon Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Altimmune Inc
Amgen Inc
Amicogen Inc
Amplifier TX AB
AptamiR Therapeutics Inc
Arrowhead Pharmaceuticals Inc
Ascletis Pharma Inc
Asdera LLC
AstraZeneca Plc
AtoGen Co Ltd
Avanti Biosciences Inc
BAR Pharmaceuticals Srl
Bast Biotechnology LLC
Belite Bio Inc
BioMarin Pharmaceutical Inc
Boehringer Ingelheim International GmbH
Bullfrog AI Inc
Can-Fite BioPharma Ltd
Changchun GeneScience Pharmaceutical Co Ltd
Chemomab Therapeutics Ltd
China NT Pharma Group Co Ltd
Corvidane
CVI Pharmaceuticals Ltd
DEUBIO
Dr. Falk Pharma GmbH
Duke University
DURECT Corp
EA Pharma Co Ltd
Eli Lilly and Co
Enspire Bio Inc
Esperion Therapeutics Inc
Eternygen GmbH
exRNA Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Fujian Cosunter Pharmaceutical Co Ltd
Future Medicine Co Ltd
Galmed Pharmaceuticals Ltd
GemVax & KAEL Co Ltd
Georgetown University
Gila Therapeutics Inc
Gilead Sciences Inc
Guangzhou BeBetter Medicine Technology Co Ltd
Haisco Pharmaceutical Group Co Ltd
Hanmi Pharmaceuticals Co Ltd
Hanyang University
Helmholtz Center Munich German Research Center for Health and Environment GmbH
HEM Pharma Inc
Hepion Pharmaceuticals Inc
HysensBio Corp
Innovent Biologics Inc
Inorbit Therapeutics AB
Inventiva SA
Ionis Pharmaceuticals Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Keystone Bio Inc
Kinomedica Pty Ltd
Kowa Co Ltd
Kylonova (Xiamen) Biopharma Co Ltd
Liminal BioSciences Inc
Lipidio Pharmaceuticals Inc
LISCure Biosciences Co Ltd
Lumos Pharma Inc
Macrophage Pharma Ltd
Macrophage Therapeutics Inc
Madrigal Pharmaceuticals Inc
MediciNova Inc
Merck & Co Inc
Metacrine Inc
Micelle BioPharma Inc
Mina Therapeutics Ltd
Modulation Therapeutics Inc
MRM Health NV
Nano Intelligent Biomedical Engineering Corp
NGM Biopharmaceuticals Inc
Nippon Chemiphar Co Ltd
Nivarta Inc
Novartis AG
NovMetaPharma Co Ltd
NuSirt Biopharma Inc
OncoTrap Inc
PegBio Co Ltd
Petri Bio LLC
Pfizer Inc
PharmaKing Co Ltd
Phenex Pharmaceuticals AG
Poxel SA
PTC Therapeutics Inc
Purpose Bio Inc
Relmada Therapeutics Inc
Renova Therapeutics Inc
Rivus Pharmaceuticals Inc
RosVivo Therapeutics Inc
Sagimet Biosciences Inc
Salix Pharmaceuticals Ltd
Scohia Pharma Inc
Shaanxi Micot Technology Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Skye Bioscience Inc
Spark Biopharma Inc
Stemirna Therapeutics Ltd
Sumitomo Dainippon Pharma Oncology
Inc
Suzhou Xingyao Kunze Bio-Pharmaceutical Co Ltd
Sveikatal Inc
T3D Therapeutics Inc
TaiwanJ Pharmaceuticals Co Ltd
TES Pharma SRL
Theratechnologies Inc
Theriva Biologics Inc
Tiximed Inc
Tohoku University
University of Barcelona
Unravel Biosciences
Verseon Corp
VGI Health Technology
Viking Therapeutics Inc
Zedira GmbH
Zhuhai United Laboratories Co Ltd
Zydus Lifesciences Ltd